Presentation is loading. Please wait.

Presentation is loading. Please wait.

Combination with IGF1R, PI3K inhibitors

Published byMaximillian Eaton Modified over 6 years ago

Similar presentations

Presentation on theme: "Combination with IGF1R, PI3K inhibitors"— Presentation transcript:

1 Combination with IGF1R, PI3K inhibitors
1. mTOR activated tumors Optimize rapalogs Combination with IGF1R, PI3K inhibitors Personalized reversal of loops ? 2. mTOR-addicted tumors ATP-competitive inhibitors Targeted therapies ? 1st line therapy Intrinsic resistance 4EBP1/ eIF4E expression Combination with eIF4E inhibitors coexisting oncogenic mutation Combination therapy K-Ras mutations Everolimus sensitivity High sensitivity 3. Magnitude of everolimus efficacy in LKB1-AMPK or PI3K-AKT activated pathway ? In order to differenciate mTor and PI3K inhibitors

Download ppt "Combination with IGF1R, PI3K inhibitors"

Similar presentations

Targeting the IGF Pathway in Pediatric Sarcomas-Lessons Learned and Questions Raised Lee J. Helman, M.D. Scientific Director for Clinical Research,Center.

Targeting the IGF Pathway in Pediatric Sarcomas-Lessons Learned and Questions Raised Lee J. Helman, M.D. Scientific Director for Clinical Research,Center.
TSC and LAM: Current Treatment Options and Clinical Trials

TSC and LAM: Current Treatment Options and Clinical Trials
Preclinical Models for Developing Therapy for Pediatric Solid Tumors Preclinical Models for Developing Therapy for Pediatric Solid Tumors uses and limitations.

Preclinical Models for Developing Therapy for Pediatric Solid Tumors Preclinical Models for Developing Therapy for Pediatric Solid Tumors uses and limitations.
Metabolic Syndrome: Focused on AMPK as Molecular Target for Metabolic Syndrome Bayu Lestari.

Metabolic Syndrome: Focused on AMPK as Molecular Target for Metabolic Syndrome Bayu Lestari.
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma by Thomas E. Witzig,

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma by Thomas E. Witzig,
Systemic treatment of renal cell cancer: A comprehensive review

Systemic treatment of renal cell cancer: A comprehensive review
TARGETING HSP90 IN IM-RESISTANT GIST:

TARGETING HSP90 IN IM-RESISTANT GIST:
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
PI3K inhibition does not Effect the BH3 Profile of SW620 Cells

PI3K inhibition does not Effect the BH3 Profile of SW620 Cells
Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.

Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.
Targeting signal transduction

Targeting signal transduction
by Rogelio Zamilpa, and Merry L. Lindsey

by Rogelio Zamilpa, and Merry L. Lindsey
Metastatic HER2+ Breast Cancer: Resistance

Metastatic HER2+ Breast Cancer: Resistance
Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma  Fred C. Lam, Michael B. Yaffe  Cancer.

Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma  Fred C. Lam, Michael B. Yaffe  Cancer.
LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT  Jacob M. Kaufman,

LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT  Jacob M. Kaufman,
PI3K Pathway Inhibitors

PI3K Pathway Inhibitors
Overall Program Goals. Overall Program Goals Current Approaches.

Overall Program Goals. Overall Program Goals Current Approaches.
تحليل الحساسية Sensitive Analysis.

تحليل الحساسية Sensitive Analysis.
Figure 1: Assessment of eribulin activity in twenty-five cell lines

Figure 1: Assessment of eribulin activity in twenty-five cell lines
IRS-1: Auditing the effectiveness of mTOR inhibitors

IRS-1: Auditing the effectiveness of mTOR inhibitors

Similar presentations

Ads by Google